Biogen financials
$227.07−0.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B | $2.53B |
| Gross profit | $1.96B | $1.82B | $1.78B | $1.86B | $2.04B | $1.80B | $1.87B | $1.83B | $1.92B | $1.75B | $1.77B | $1.87B |
| Gross margin | 71.6% | 73.3% | 78.3% | 73.4% | 77.1% | 74.1% | 76.2% | 74.1% | 77.8% | 76.3% | 74.1% | 73.9% |
| Operating income | $150.9M | $397.4M | $98.4M | $591.4M | $792.7M | $379.6M | $441.4M | $465.8M | $695.3M | $464.8M | $358.9M | $158.8M |
| Net income | $97.5M | $319.5M | -$48.9M | $466.5M | $634.8M | $240.5M | $266.7M | $388.5M | $583.6M | $393.4M | $249.7M | -$68.1M |
| Net margin | 3.6% | 12.9% | −2.1% | 18.4% | 24.0% | 9.9% | 10.9% | 15.8% | 23.7% | 17.2% | 10.5% | −2.7% |
| Diluted EPS | $0.66 | $2.15 | $-0.33 | $3.17 | $4.33 | $1.64 | $1.83 | $2.66 | $4.00 | $2.70 | $1.70 | $-0.47 |
| EBITDA | $554.9M | $609.7M | $329.7M | $806.6M | $999.5M | $598.1M | $606.9M | $767.8M | $772.2M | $767.7M | $457.7M | $359.8M |
| Operating cash flow | $448.9M | $645.5M | $511.9M | $1.27B | $160.9M | $259.3M | $760.9M | $935.6M | $625.8M | $553.2M | $12.5M | $592.4M |
| Free cash flow | $408.0M | $594.3M | $468.0M | $1.23B | $134.3M | $222.2M | $721.6M | $900.6M | $592.3M | $507.3M | -$52.7M | $518.2M |
| Diluted shares | 148.7M | 148.4M | 148.0M | 147.1M | 146.7M | 146.6M | 145.7M | 146.1M | 145.9M | 145.9M | 146.9M | 144.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.28B | $3.38B | $3.01B | $3.86B | $2.76B | $2.60B |
| Short-term investments | $0.00 | $900.0M | $807.2M | $97.6M | $0.00 | $0.00 |
| Total debt | $8.09B | $6.29B | $6.29B | $6.29B | $6.28B | $6.30B |
| Total assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B |
| Total liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B |
| Shareholders' equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology